Announcements Trials
Browse Landscape

Status

Completed 4Recruiting 2

Sponsor Class

OTHER 7INDUSTRY 6

Study Type

Interventional 55Observational 6Expanded_access 1

Sponsor

Cancer Type

Breast 2Thoracic 1Genitourinary 1Classical hematology 1

Conditions

Breast Neoplasms 468Neoplasms 316Carcinoma, Non-Small-Cell Lung 269Prostatic Neoplasms 215Colorectal Neoplasms 208Lung Neoplasms 178Multiple Myeloma 123Melanoma 110Carcinoma, Renal Cell 107Ovarian Neoplasms 94Carcinoma, Hepatocellular 78Pancreatic Neoplasms 69Urinary Bladder Neoplasms 65Stomach Neoplasms 64Neoplasm Metastasis 64Leukemia, Lymphocytic, Chronic, B-Cell 62Colonic Neoplasms 60Leukemia, Myeloid, Acute 53Uterine Cervical Neoplasms 50Recurrence 49Liver Neoplasms 46Lymphoma, Follicular 45Lymphoma 45Leukemia, Myelogenous, Chronic, BCR-ABL Positive 39Esophageal Neoplasms 37Precursor Cell Lymphoblastic Leukemia-Lymphoma 36Lymphoma, Large B-Cell, Diffuse 35Hematologic Neoplasms 35Head and Neck Neoplasms 35Lymphoma, Non-Hodgkin 34

Interventions

Alpelisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
INDUSTRY × Observational × Hereditary Sensory and Autonomic Neuropathies × Clear all
NCT06494540 2026-05-22

NAUTIC

AstraZeneca

Recruiting
600 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Hereditary Sensory and Autonomic Neuropathies

NCT05868629 2026-04-01

Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors

Novartis

Recruiting
40 enrolled

Hereditary Sensory and Autonomic Neuropathies

NCT04480814 2025-12-30

Validation of Molecular Diagnostic Assays to Detect Cancer Biomarkers in Blood & Primary Tumor in ER+/HER2- MBC

Pharmassist Ltd

Completed
30 enrolled
Breast

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT05982886 2023-08-09

Biomarker Testing and Treatment Patterns Among Patients With PIK3CA Mutation in Advanced Breast Cancer

Novartis

Completed
1,093 enrolled
Breast

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT04285723 2023-02-09

EPIK-P1

Novartis

Completed
57 enrolled 23 charts 1 FDA

Hereditary Sensory and Autonomic Neuropathies

NCT04425200 2021-12-07

ZENSHIN

AstraZeneca

Completed
205 enrolled
Classical hematologyGenitourinary

Fanconi Anemia, Complementation Group D1, Hereditary Sensory and Autonomic Neuropathies, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡